These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 22973979)

  • 21. Role of BRAF V600E mutation as an indicator of the extent of thyroidectomy and lymph node dissection in conventional papillary thyroid carcinoma.
    Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
    Surgery; 2015 Dec; 158(6):1500-11. PubMed ID: 26120069
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.
    Xing M; Alzahrani AS; Carson KA; Viola D; Elisei R; Bendlova B; Yip L; Mian C; Vianello F; Tuttle RM; Robenshtok E; Fagin JA; Puxeddu E; Fugazzola L; Czarniecka A; Jarzab B; O'Neill CJ; Sywak MS; Lam AK; Riesco-Eizaguirre G; Santisteban P; Nakayama H; Tufano RP; Pai SI; Zeiger MA; Westra WH; Clark DP; Clifton-Bligh R; Sidransky D; Ladenson PW; Sykorova V
    JAMA; 2013 Apr; 309(14):1493-501. PubMed ID: 23571588
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer.
    Liu X; Qu S; Liu R; Sheng C; Shi X; Zhu G; Murugan AK; Guan H; Yu H; Wang Y; Sun H; Shan Z; Teng W; Xing M
    J Clin Endocrinol Metab; 2014 Jun; 99(6):E1130-6. PubMed ID: 24617711
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BRAF and NRAS Mutations in Papillary Thyroid Carcinoma and Concordance in BRAF Mutations Between Primary and Corresponding Lymph Node Metastases.
    Fakhruddin N; Jabbour M; Novy M; Tamim H; Bahmad H; Farhat F; Zaatari G; Aridi T; Kriegshauser G; Oberkanins C; Mahfouz R
    Sci Rep; 2017 Jul; 7(1):4666. PubMed ID: 28680105
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma.
    Zou M; Baitei EY; Alzahrani AS; BinHumaid FS; Alkhafaji D; Al-Rijjal RA; Meyer BF; Shi Y
    Thyroid; 2014 Aug; 24(8):1256-66. PubMed ID: 24798740
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Follicular cell (papillary and follicular) thyroid carcinoma, genetic inheritance, and molecular diagnostic markers].
    Kazubskaia TP; Kozlova VM; Kondrat'eva TT; Pavlovskaia AI; Marakhonov AV; Baranova AV; Ivanova NI; Stepanova AA; Poliakov AV; Belev NF; Brzhezovskiĭ VZh
    Arkh Patol; 2014; 76(5):3-12. PubMed ID: 25543402
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BRAF(V600E) mutation analysis in papillary thyroid carcinoma: is it useful for all patients?
    Ito Y; Yoshida H; Kihara M; Kobayashi K; Miya A; Miyauchi A
    World J Surg; 2014 Mar; 38(3):679-87. PubMed ID: 24052184
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience.
    Gouveia C; Can NT; Bostrom A; Grenert JP; van Zante A; Orloff LA
    JAMA Otolaryngol Head Neck Surg; 2013 Nov; 139(11):1164-70. PubMed ID: 24030686
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Association between BRAF V600E mutation and central lymph node metastasis in patients with papillary thyroid carcinoma].
    Shi C; Qin H; Ding C; Sun Y; Lyu Y; Shi T
    Zhonghua Zhong Liu Za Zhi; 2015 Feb; 37(2):123-7. PubMed ID: 25975689
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinicopathologic implications of the BRAF(V600E) mutation in papillary thyroid cancer: a subgroup analysis of 3130 cases in a single center.
    Lim JY; Hong SW; Lee YS; Kim BW; Park CS; Chang HS; Cho JY
    Thyroid; 2013 Nov; 23(11):1423-30. PubMed ID: 23496275
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Study on the correlation between BRAF(V600E) mutation and lymphatic metastases in papillary thyroid cancer staged preoperativelv as N0].
    Gao Q; Zhang W; Wang N; Duan H; Zhou Y; Zhang W; Zhao D
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Dec; 29(23):2048-52. PubMed ID: 27101676
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk and Prognostic Factors for BRAF
    Wei X; Wang X; Xiong J; Li C; Liao Y; Zhu Y; Mao J
    Biomed Res Int; 2022; 2022():9959649. PubMed ID: 35647194
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer.
    Kim SJ; Lee KE; Myong JP; Park JH; Jeon YK; Min HS; Park SY; Jung KC; Koo do H; Youn YK
    World J Surg; 2012 Feb; 36(2):310-7. PubMed ID: 22190222
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Confirmation of papillary thyroid cancer susceptibility loci identified by genome-wide association studies of chromosomes 14q13, 9q22, 2q35 and 8p12 in a Chinese population.
    Wang YL; Feng SH; Guo SC; Wei WJ; Li DS; Wang Y; Wang X; Wang ZY; Ma YY; Jin L; Ji QH; Wang JC
    J Med Genet; 2013 Oct; 50(10):689-95. PubMed ID: 23847140
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Correlation between BRAF V600E mutation and clinicopathologic features of papillary thyroid carcinoma].
    Lu H; Qiu T; Ying J; Guo C; Lyn N
    Zhonghua Bing Li Xue Za Zhi; 2014 Dec; 43(12):794-8. PubMed ID: 25623974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Papillary microcarcinoma of the thyroid: clinical characteristics and BRAF(V600E) mutational status of 977 cases.
    Zheng X; Wei S; Han Y; Li Y; Yu Y; Yun X; Ren X; Gao M
    Ann Surg Oncol; 2013 Jul; 20(7):2266-73. PubMed ID: 23370668
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer.
    Fraser S; Go C; Aniss A; Sidhu S; Delbridge L; Learoyd D; Clifton-Bligh R; Tacon L; Tsang V; Robinson B; Gill AJ; Sywak M
    World J Surg; 2016 Jul; 40(7):1618-24. PubMed ID: 27138882
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRAF analysis before surgery for papillary thyroid carcinoma: correlation with clinicopathological features and prognosis in a single-institution prospective experience.
    Galuppini F; Pennelli G; Vianello F; Censi S; Zambonin L; Watutantrige-Fernando S; Manso J; Nacamulli D; Lora O; Pelizzo MR; Rugge M; Barollo S; Mian C
    Clin Chem Lab Med; 2016 Sep; 54(9):1531-9. PubMed ID: 26863344
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TSHR rs2288496 associated with thyroid hormone and predict the occurrence of lymph node metastasis of papillary thyroid cancer.
    Su X; Lin LW; Weng JL; Chen SW; Yang XH; Zhou DL; Long YK; Shao Q; Ye ZL; Peng JL; Deng L; He CY; Yang AK
    Cancer Biomark; 2019; 26(4):461-470. PubMed ID: 31658048
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The relationship of the BRAF(V600E) mutation and the established prognostic factors in papillary thyroid carcinomas.
    Kurt B; Yalçın S; Alagöz E; Karslıoğlu Y; Yigit N; Günal A; Deveci MS
    Endocr Pathol; 2012 Sep; 23(3):135-40. PubMed ID: 22767446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.